Paysign names Jose Garcia as EVP of life science solutions

HENDERSON, Nev. - Paysign, Inc. (NASDAQ:PAYS), a fintech company whose stock has surged over 140% in the past six months, has appointed Jose Garcia as Executive Vice President, Life Science Solutions, according to a company press release issued Monday. According to InvestingPro data, the company currently trades slightly below its Fair Value, suggesting potential upside opportunity.

In his new position, Garcia will implement and execute market strategy for Paysign’s suite of engagement and management solutions for the life sciences industries. He joins the $306 million market cap company at a time of significant growth, with revenue increasing nearly 28% over the last twelve months. He brings over two decades of executive experience to the role, having previously served as Vice President, Client Relationships at QualTex Laboratories, where he strengthened partnerships in the blood and plasma collection industries.

Prior to QualTex, Garcia held Vice President of Sales positions at BioBridge Global companies QualTex and GenCure, where he developed strategies that expanded the company’s footprint in the life sciences sector.

"Jose is a proven leader with deep expertise in the plasma collection industry as well as the broader life sciences industry," said Mark Newcomer, President and CEO of Paysign. "His success in sales and client engagement makes him the perfect fit to spearhead the commercialization of our engagement and management software platforms."

Garcia expressed his enthusiasm about joining the company, stating, "I am honored to join Paysign at such a pivotal time. I look forward to contributing to the company’s continued growth and innovation in serving the blood, plasma, and broader life sciences industries."

Paysign operates at the intersection of fintech and healthcare, providing patient affordability programs, donor compensation solutions, and management platforms for the plasma, pharmaceutical and life sciences industries. The company’s proprietary architecture supports various payment methods with real-time transaction intelligence. With a robust gross profit margin of 60% and an overall "GOOD" financial health rating from InvestingPro, which offers comprehensive analysis and 8 additional key insights about the company’s performance and valuation, Paysign appears well-positioned for continued growth in its market segment.

In other recent news, Paysign Inc. reported its second-quarter 2025 earnings with a record revenue of $19.1 million, surpassing forecasts of $18.67 million. However, the company’s earnings per share (EPS) fell short, coming in at $0.02 compared to the anticipated $0.03. In addition to these earnings results, Paysign has opened a new 30,000 square foot patient service support center in Henderson, Nevada. This facility is expected to quadruple the company’s support capacity, aligning with the significant 190% year-over-year revenue growth in its patient affordability business during the second quarter. DA Davidson has raised its price target for Paysign to $9.00 from $8.00, maintaining a Buy rating. This adjustment follows Paysign’s impressive 33% year-over-year growth in total revenue and a 102% increase in adjusted EBITDA. These developments highlight Paysign’s ongoing expansion and financial performance, capturing the attention of both analysts and investors.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.